Trillium Therapeutics Inc. (TTI), a biopharmaceutical company developing innovative immune-based biologics, announced that it has entered into two definitive license agreements with University Health Network (UHN) and The Hospital for Sick Children (SickKids) in Toronto, Ontario, granting...
Trillium Therapeutics Inc. (TTI), a biopharmaceutical company developing innovative immune-based biologics, announced that it has entered into two definitive license agreements with University Health Network (UHN) and The Hospital for Sick Children (SickKids) in Toronto, Ontario, granting...